Literature DB >> 11054398

Hepatitis C in African Americans: summary of a workshop.

C Howell1, L Jeffers, J H Hoofnagle.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 11054398     DOI: 10.1053/gast.2000.19582

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  28 in total

Review 1.  Treatment of chronic hepatitis C in nonresponders to previous therapy.

Authors:  Todd E Dantzler; Eric J Lawitz
Journal:  Curr Gastroenterol Rep       Date:  2003-02

2.  Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.

Authors:  Raymond T Chung; Michael Gale; Stephen J Polyak; Stanley M Lemon; T Jake Liang; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Racial differences in hepatitis C treatment eligibility.

Authors:  Michael T Melia; Andrew J Muir; Jonathan McCone; Mitchell L Shiffman; John W King; Steven K Herrine; Greg W Galler; Joseph R Bloomer; Frederick A Nunes; Kimberly A Brown; Kevin D Mullen; Natarajan Ravendhran; Reem H Ghalib; Navdeep Boparai; Ruiyun Jiang; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

4.  Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C.

Authors:  Dickens Theodore; Mitchell L Shiffman; Richard K Sterling; Christine J Bruno; Jeffrey Weinstein; Jeffrey S Crippin; Gabriel Garcia; Teresa L Wright; Hari Conjeevaram; Rajender K Reddy; Frederick S Nolte; Michael W Fried
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

5.  Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.

Authors:  P J Thuluvath; A Maheshwari; J Mehdi; K D Fairbanks; L L-W Wu; L G Gelrud; M J Ryan; F A Anania; I F Lobis; M Black
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 6.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

7.  Risk factors for hepatocellular carcinoma in patients with cirrhosis.

Authors:  Steedman A Sarbah; Terry Gramlich; Abraham Younoszai; Pat Osmack; Marlene Goormastic; Leonard Grosso; James N Cooper; Adrian Di Bisceglie; Russell Seneca; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

8.  Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

Authors:  Christine M Rousseau; George N Ioannou; Jeffrey A Todd-Stenberg; Kevin L Sloan; Meaghan F Larson; Christopher W Forsberg; Jason A Dominitz
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

9.  Demographics of a large cohort of urban chronic hepatitis C patients.

Authors:  Firdous A Siddiqui; Murray N Ehrinpreis; James Janisse; Ravi Dhar; Elizabeth May; Milton G Mutchnick
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

10.  Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans.

Authors:  Rebecca A Harris; Kazushi Sugimoto; David E Kaplan; Fusao Ikeda; Malek Kamoun; Kyong-Mi Chang
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.